10 Best Performing Pharma Stocks So Far in 2025

8. Beam Therapeutics Inc. (NASDAQ:BEAM)

YTD Performance: 34.29%

Number of Hedge Fund Holders: 35

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines through base editing, a technology that allows efficient and predictable single base changes at targeted genomic sequences. The company’s lead programs focus on sickle cell disease and alpha-1 antitrypsin deficiency. Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing programs in other genetic diseases as well, along with oncology and immunology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201.

In June, the company attained IND clearance for its second in-vivo program, BEAM-301, which treats glycogen storage disease 1a (GSD1a). Since then, its team has been advancing BEAM-301 into the clinic, with site activation underway and patient dosing expected to commence in early 2025.

Beam Therapeutics Inc. (NASDAQ:BEAM) also exhibited strong execution across its priority hematology and liver genetic disease programs in fiscal Q3 2024, with progress in patient enrollment, clinical site activation, and dosing. It is entering 2025 at a significant inflection point in the company’s evolution, having advanced four programs into the clinic, established clinical differentiation for base editing with its lead sickle cell disease program, and prioritized two high-value core franchises. As of September 30, 2024, Beam Therapeutics Inc. (NASDAQ:BEAM) has cash, cash equivalents, and marketable securities worth $925.8 million.